Maternal HIV Disclosure to School Children: RCT of Family-based Intervention (Amagugu)
|ClinicalTrials.gov Identifier: NCT01922882|
Recruitment Status : Completed
First Posted : August 14, 2013
Last Update Posted : August 23, 2016
|First Submitted Date ICMJE||July 8, 2013|
|First Posted Date ICMJE||August 14, 2013|
|Last Update Posted Date||August 23, 2016|
|Start Date ICMJE||May 2013|
|Primary Completion Date||September 2015 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Change in disclosure [ Time Frame: Baseline, 3 months, 6 months and 9 month post baseline ]
Measures the proportion of HIV-infected women in the intervention and control arms who, within 3, 6 and 9-months disclose their HIV status to their 6-9 year old HIV-uninfected child.
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01922882 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE
||Change in health perceptions [ Time Frame: Baseline and 9 months post baseline ]
Measure baseline health perceptions and changes in health perceptions at the study endpoint using the Medical Outcomes Study (MOS-36)
|Original Other Outcome Measures ICMJE||Same as current|
|Brief Title ICMJE||Maternal HIV Disclosure to School Children: RCT of Family-based Intervention|
|Official Title ICMJE||Maternal HIV Disclosure to School Children: RCT of Family-based Intervention (Amagugu)|
|Brief Summary||The purpose of this trial is to test whether, compared to the normal Standard of Care at primary health care clinics, a home-based counseling intervention ( the 'Amagugu' Counseling Intervention), will increase the number of HIV-infected mothers who are able to disclose their own HIV status to their primary school-aged children. The investigators also wish to examine whether the intervention improves the quality of the maternal-child relationship, emotional and well-being of the child and social support.|
The primary aim of this clinical trial is to test the efficacy of an intervention which aims to increase rates of maternal HIV disclosure to HIV-uninfected children aged 6-9 years.
Secondary aims include to improve:
We hypothesize that our intensive home-based intervention (the 'Amagugu' Counseling Intervention), compared to the Standard of Care in clinic facilities, will significantly increase rates of maternal HIV disclosure and will result in improvements in the quality of the maternal-child relationship, emotional well-being of children and family support.
The intervention package was successfully piloted in late 2010 (Rochat et al 2013, BMC Public Health) and a large scale feasibility and acceptability field test was completed with 281 families in April 2012 funded by the Canadian International Development Agency. Preliminary results show that the intervention is highly acceptable, with more than 90% of mothers agreeing to participate; and effective with more than 90% having disclosed to their child either 'fully' (using the words 'HIV' and explaining that they have HIV) or 'partially' (using the word 'virus' and explaining that they have this virus).
Sample size calculation
Based on our pilot work we have shown that at least 60% of mothers disclosed their HIV status fully during the intervention. However, our results also show that prior disclosure to a current partner at baseline significantly increases the odds of full disclosure to children following the intervention. Since women enrolled in this trial will already be in HIV care they are likely to have received counseling and support to disclose their HIV status to their partners. To allow for the possibility of this effect in both intervention and control arms, we have powered the study conservatively to ensure that we have adequate power to detect differences between the groups. We have assumed that 30% women in the control arm will disclose their HIV status to their children in this trial and that the intervention will increase the proportion disclosing their HIV status to their children by at least 15 percentage points. Allowing for a loss-to-follow-up of 20%, 300 mothers in the intervention arm and 300 in the control arm will provide >90% power to detect a difference of 30% versus 45% (alpha type-one error of 5%, two-tailed) in HIV disclosure to children. This design will also provide adequate power for our main secondary outcome which is children's social and emotional wellbeing measured by the Child Behavior Checklist (Achenbach & Ruffle, 2000) as described in the objectives above. In high risk populations of children, one would expect the mean CBCL total score to be 50 for boys and for girls, with a standard deviation of 10. We hypothesize that our intervention would decrease the CBCL total difficulties score by at least 3 points whilst there would be no change in the CBCL score in the control group. With 300 women in each group we would have >90% power to detect a difference of 3 points between control and intervention.
The research site
The proposed research will be managed from the Wellcome Trust-funded Africa Centre. Recruitment will take place at a primary health care clinic located 1 km from the Africa Centre headquarters. Participants will be enrolled from an established HIV Programme, including (i) pre-ART patients who attend clinics on a 6-monthly basis to assess eligibility for ART based on immunological (CD4 cell count) and clinical staging and (ii) patients already on ART. Recruitment will be monitored carefully and if numbers are not sufficient we will seek ethics permission to expand to additional clinics.
All 600 mothers (i.e. 300 in the intervention and 300 in the Standard of Care arms) will receive assessments at four time points: at enrollment by the CRA and at home by one study interviewer as follows:
Time point 1: Baseline assessment at enrollment at clinic (CRA) Time point 2: 3-month assessment at home (study interviewer) Time point 3: 6-month assessment at home (study interviewer) Time point 4: 9-month assessment at home (study interviewer)
All assessments will be conducted in isiZulu and the study interviewer will be blinded to whether the mothers are randomized to the intervention or Standard of Care.
Data collection will be completed using mobile phones that will digitally capture and transmit data from the field sites (clinic and women's homes) to the Africa Centre. Using the key pad the research staff will load a mobile researcher application on the phone which will display the questionnaires and assessments to be completed. On completion of the questions and assessments, the answers will be stored securely on the handsets until the phone is in the range of a mobile phone signal tower. There is a signal tower situated adjacent to the Africa Centre, and signal strength in the area of the proposed research clinic is generally excellent. When in range, the phones will automatically and securely upload the data to the central database.
Whilst the main data capture method will be the mobile phones, paper forms will be used for (i) informed consent, (ii) participant tracking information. These forms will be transported weekly from the clinic to the Africa Centre and stored in a secure Data Centre.
The Africa Centre has Standard Operating Procedures in place to track forms between the field, clinics and Centre, with clear documentation to identify 'chains of custody' as forms are handed between staff. In addition, a book containing a list of participating mothers and their unique study ID will be kept in a locked cabinet in the clinic; this will only be accessible by study staff. All files and data in the clinic are treated with the strictest of confident. The two paper forms and this book will be the only places where an individual's personal details are linked to their unique study ID.
Following uploading, data will be checked for completeness and accuracy the following day by the study coordinator; with queries returned to the field staff within 48 hours for correction.
Data cleaning will occur fortnightly, with routine checks for inaccuracies, outlying values and missing data, with immediate feed-back to the field team for rectification.
An intention-to-treat analysis, based on the randomization, will be used for the primary trial outcome - proportion of HIV-infected women who disclose to their HIV-uninfected child at 3, 6 and 9-months.
Because of the possibility that the randomization may lead to some imbalance in the distribution of risk factors across the trial arms, an assessment for baseline characteristics known to be associated with disclosure will be undertaken using binary logistic regression. These include age and gender of the child, mother's age, marital status and family composition, mother's health status, and educational attainment that will be collected as part of the study.
We will report both adjusted and unadjusted effects of the intervention on disclosure. The outcomes related to taking children on a health promotion visit to the clinic and developing a clear custody care plan will be analyzed using the same methodology.
The Child Behavior Check List (CBCL) scale is a multi-axial, empirically-based measure for assessing children's mental health and behavior by parent report. It consists of 120 items, measuring eight constructs or syndromes ( Withdrawn, Somatic complaints, Anxious/Depressed, Social Problems, Thought Problems, Attention Problems, Delinquent behavior, Aggressive behavior) and allowing for examination of two broad grouping of syndromes: Internalizing and Externalizing problems.
Raw scores can be converted to T scores to facilitate comparisons across the sub-scales, computing a Total Internalizing, Externalizing and Competence Score as well as a Total score. T scores from 50 to 70 are based on percentiles from normative samples of non- referred children. For statistical analysis of syndrome scales in this research, raw scale scores will be used and not T scores, in order to take account of the full range of variation in the scales. Scores will be standardized taking age and gender into account.
The CBCL has been cross-culturally validated, and translated for use in this research community and was used as a measure in the preliminary work by the applicants. In line with normative research we expect a mean of 50 and a standard deviation of 10. The analysis to compare changes in emotional and behavioral difficulties in children using the CBCL scale will be performed on an intention-to-treat analysis. Baseline comparability across the trial arms using the CBCL subscales will be assessed in subjects to address comparability by randomization assignment.
The statistical significance of changes in total CBCL scores from baseline to 9-month follow-up, within the control and intervention groups separately, will be calculated using t tests for normally distributed outcome measures. If baseline disparities across treatment arms are identified, then we will also perform linear regression analysis to allow adjustment for baseline disparities.
Data safety and monitoring plan
The quality of data collection and management will be monitored throughout the trial.
The use of mobile technology will result in several advantages in terms of data quality and management including: built in algorithms and skip patterns to ensure data are collected with accuracy, consistency and integrity; and 'real time' transmission of data collected in the field to the Africa Centre Data Centre, ensuring rapid data cleaning.
A Data Safety and Monitoring Board has been established and the terms of reference agreed.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
|Intervention ICMJE||Behavioral: Amagugu Counseling Intervention
6-session home-based counseling intervention delivered by lay counselors at mothers' homes
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||September 2015|
|Primary Completion Date||September 2015 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||16 Years and older (Child, Adult, Senior)|
|Accepts Healthy Volunteers||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||South Africa|
|Removed Location Countries|
|NCT Number ICMJE||NCT01922882|
|Other Study ID Numbers ICMJE||1R01HD074267-01( U.S. NIH Grant/Contract )|
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||University of KwaZulu|
|Study Sponsor ICMJE||University of KwaZulu|
|Collaborators ICMJE||Not Provided|
|PRS Account||University of KwaZulu|
|Verification Date||August 2016|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP